期刊文献+

红河州HIV/HCV合并感染者HCV基因亚型多样性及种系进化研究 被引量:5

Genotypes diversity and phylogenetic analysis of HCV in HIV/HCV co-infection patients in Honghe
下载PDF
导出
摘要 目的探讨云南省红河州地区HIV/HCV合并感染者HCV基因亚型多样性及种系进化情况,为本地区HIV/HCV合并感染者合理的抗病毒治疗提供科学依据,同时监测该类患者体内的HCV是否存在遗传进化的新变异。方法扩增55名红河州内HIV/HCV合并感染的HCV病毒载量阳性的丙型肝炎患者C/E1和NS5B 2个基因位点,通过测序分析和种系进化分析以明确研究对象所感染的HCV病毒的基因型和亚型。结果综合2个外显子序列分析,结果显示红河州HIV/HCV合并感染患者的HCV以3b亚型最多见(40.0%),其次是3a(20.0%)、6a(16.4%)、6n(12.7%)、1b(9.1%)、双重感染(1.8%)。课题组做本地区HCV基因亚型遗传进化分析时发现红河州地区流行的6a亚型毒株序列均与越南的HCV 6a亚型毒株的参考序列丛集。结论 HCV 6a亚型是越南和红河州内静脉吸毒人群(intravenous drug uses,IDUs)中高流行的病毒亚型,由于与越南接壤,红河州可能是HCV 6a亚型通过静脉吸毒途径由越南传入中国流行的一个传入点,进而再传入昆明或中国的其它地区。 Objective To investigate the diversity of HCV genotype and phylogenesis in HIV/HCV co-infection patients in Honghe of Yunnan province. On one hand, it will provide reasonable therapy for the patients; on the other hand, we can supervise new variants of HCV in this area. Methods 55 HIV/HCV co- infection patients, who tested sere-positive and HCV-RNA positive, were recruited into this study. 2 regions of HCV gene, C/E1 and NS5B were PCR- amplified, sequenced and phylogenetically analyzed. Results Sequencing results of the 2 coding regions showed that subtype 3b was the most predominant (40.0%), followed by 3a (20.0%), 6a (16.4%), 6n (12.7%), lb (9.1%), and lastly dual-infection (1.8%). Phylogentic analysis showed that subtype 6a strain from Honghe was clustered with reference sequence from Vietnam. Conclusion HCV 6a is a high prevalent subtype in intravenous drug users (IDUs) both in Vietnam and Honghe. Due to bordering Vietnam, Honghe might be one of the dissemination entrance points of HCV subtype 6a from Vietnam to China with the main transmission route of IDU.
出处 《分子诊断与治疗杂志》 2018年第1期17-24,共8页 Journal of Molecular Diagnostics and Therapy
基金 红河州第一人民医院院内基金(KY201409)
关键词 丙型肝炎 基因型 基因亚型 种系进化分析 Hepatitis C Genotype Subtype Phylogenetic analysis
  • 相关文献

参考文献2

二级参考文献164

  • 1谢尧,赵辉,鸥蔚妮,闫杰,杜邵财,徐道振.不同感染途径慢性丙型肝炎患者HCV基因型分布的差异[J].中华实验和临床病毒学杂志,2004,18(3):247-250. 被引量:30
  • 2杨东亮,郝连杰.我国丙型肝炎病毒基因变异及分型研究现状[J].中华传染病杂志,1996,14(1):41-44. 被引量:26
  • 3Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, et al.Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Rev Invest Clin, 2003,55(2):138-142.
  • 4Inoue K, Sekiyama K, Yamada M, et al. Combined interferon alpha2h and cyclosporin A in the treatment of chronic hepatitis C:controlled trial. J Gastroenterol, 2003, 38(6): 567-572.
  • 5Berg T, Kronenberger B, Hinrichsen H, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology, 2003, 37(6): 1359-1367.
  • 6Simmonds P. Genetic diversity and evolution of hepatitis Cvirus-15 years on. J Gen Virol 2004; 85: 3173-3188 [PMID:15483230 DOI: 10.1099/vir.0.80401-0].
  • 7Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36: S21-S29 [PMID: 12407573 DOI: 10.1053/jhep.2002.36227].
  • 8Pawlotsky JM. The nature of interferon-alpha resistance inhepatitis C virus infection. Curr Opin Infect Dis 2003; 16: 587-592[PMID: 14624110 DOI: 10.1097/01.qco.0000104300.87920.03].
  • 9Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N,Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G,Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, PeninF, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, WeinerAJ, Widell A. Consensus proposals for a unified system ofnomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973 [PMID: 16149085 DOI: 10.1002/hep.20819].
  • 10Rosen HR, Gretch DR. Hepatitis C virus: current understandingand prospects for future therapies. Mol Med Today 1999; 5:393-399 [PMID: 10462751].

共引文献18

同被引文献63

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部